Skip to content

Efficacy And Safety Of injectable PRF As An Adjuvant with topical minoxidil In Treatment Of Male Patterned Baldness

Efficacy And Safety Of iPRF(Injectable Platelet Rich Fibrin) As An Adjuvant In Treatment Of Male Patterned Baldness - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056519
Enrollment
30
Registered
2023-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: injectable platelet rich fibrin: iPRF will be prepared by centrifugation and injected over scalp using insulin syringes procedure will be repeated monthly for 6 months Control Intervent

Sponsors

Krishna Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Have given written consent before any treatment is commenced. 2. Be diagnosed to be suffering from male patterned baldness by assessment through Hamilton and Norwood Scale(Grade 2 to 6) clinically in DERMATOLOGY OPD 3. Have completed 18 years of age.

Exclusion criteria

Exclusion criteria: A. Patient having keloid scarring or keloidal tendency. B. History of bleeding disorder and anticoagulant therapy. C. Active skin infection over scalp. D. Patient on any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results. E. Patients with known hypersensitivity to topical anaesthetic agents.

Design outcomes

Primary

MeasureTime frame
Reduction in hairlossTimepoint: Reduction in hairloss in 6 months

Secondary

MeasureTime frame
identification of better adjuvantTimepoint: new hair growth in 6 months

Countries

India

Contacts

Public ContactDr Balkrishna Nikam

Krishna institute of medical sciences

docmsk2@gmail.com9823087223

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026